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Background: Type 2 Diabetes Mellitus (DM) is a common chronic disease associated with multiple clinical
complications. Management guidelines have been established which recommend a risk-stratified approach to
managing these patients in primary care. This study aims to evaluate the quality of care (QOC) and effectiveness of
a multi-disciplinary risk assessment and management programme (RAMP) for type 2 diabetic patients attending
government-funded primary care clinics in Hong Kong. The evaluation will be conducted using a structured and
comprehensive evidence-based evaluation framework.
Method/design: For evaluation of the quality of care, a longitudinal study will be conducted using the Action
Learning and Audit Spiral methodologies to measure whether the pre-set target standards for criteria related to the
structure and process of care are achieved. Each participating clinic will be invited to complete a Structure of Care
Questionnaire evaluating pre-defined indicators which reflect the setting in which care is delivered, while process of
care will be evaluated against the pre-defined indicators in the evaluation framework.
Effectiveness of the programme will be evaluated in terms of clinical outcomes, service utilization outcomes, and
patient-reported outcomes. A cohort study will be conducted on all eligible diabetic patients who have enrolled
into RAMP for more than one year to compare their clinical and public service utilization outcomes of RAMP
participants and non-participants. Clinical outcome measures will include HbA1c, blood pressure (both systolic and
diastolic), lipids (low-density lipoprotein cholesterol) and future cardiovascular diseases risk prediction; and public
health service utilization rate will include general and specialist outpatient, emergency department attendances,
and hospital admissions annually within 5 years. For patient-reported outcomes, a total of 550 participants and
another 550 non-participants will be followed by telephone to monitor quality of life, patient enablement, global
rating of change in health and private health service utilization at baseline, 6, 12, 36 and 60 months.
Discussion: The quality of care and effectiveness of the RAMP in enhancing the health for patients with type 2
diabetes will be determined. Possible areas for quality enhancement will be identified and standards of good
practice can be established. The information will be useful in guiding service planning and policy decision making.
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Delivery of public-sector primary care in Hong Kong
occurs through government-funded General Out-Patient
Clinics (GOPC) managed by the Hospital Authority
(HA). There are currently 74 clinics divided into seven
geographical districts and referred to as HA clusters
servicing the population of Hong Kong requiring
government-subsidized health care. These primary care
clinics provided 4,979,754 general outpatient atten-
dances in 2010–2011 [1] and the number of atten-
dances was estimated to increase further in the coming
years. The majority of patients are elderly, of lower
socio-economic status or have chronic diseases which
require regular monitoring or medication such as
hypertension and diabetes mellitus.
Type 2 diabetes mellitus (DM) is a major cause of
morbidity and was the ninth commonest cause of death
in Hong Kong in 2008 [2]. There are approximately
190,000 patients receiving care for DM in the GOPC
according to data from HA. Until recently however,
there have not been any formal standardized guidelines
or protocols regarding the delivery of care for diabetic
patients within the public primary care setting. In August
2009, the HA introduced a multi-disciplinary Risk As-
sessment and Management Programme (RAMP) to im-
prove the quality of care for patients receiving diabetic
care in the GOPCs. The RAMP utilizes a standardized
protocol consisting of a workflow of checking of relevant
clinical parameters including HbA1c, blood pressure
(BP), low density lipoprotein-cholesterol (LDL-C), and
an agreed risk assessment criteria for risk level stratifica-
tion, with different management options assigned to
patients of different risk levels and with different needs.
Patients with DM who are independent in their activities
of daily living and being followed up at regularly at the
GOPCs are eligible to enter the RAMP. All enrolled
patients undergo a comprehensive risk assessment and
screening for diabetes-related complications, and are
then assigned to receive appropriate interventions and
education provided by a team of multi-disciplinary
healthcare professionals according to their stratified risk
level. Low risk patients continue with the usual GOPC
follow up, medium risk patients are given additional
intervention by an advanced practice nurse (APN), and
high risk/very high risk patients are given additional
intervention by an APN and an associate consultant,
who is a specialist family physician. The RAMP is
repeated once at least every one to two years for all
patients who are enrolled.
A review of the international literature on risk stratifi-
cation of diabetic patients supports the benefit of identi-
fying high-risk patients through the clinical information
system [3]. Risk factors can be identified based on the level
of glycaemic control and/or presence of complicationswhere improvement in HbA1c, BP, and LDL-C can be
achieved through more intensive interventions [3,4].
Moreover, health service utilization such as Accidents and
Emergency (A&E) department attendance, consultations,
and hospital admissions can also be reduced [5,6]. A num-
ber of non-Asian countries have already successfully
adopted such stratified models for chronic diabetic care
including the United Kingdom, Australia, New Zealand
and Canada [7-11].
In Asia, the Joint Asia Diabetes Evaluation (JADE)
Program, incorporating a comprehensive risk engine,
care protocol, clinical decision and self-management
support has recently been developed to improve ambula-
tory diabetes care [12]. Although the JADE was deve-
loped based on data from patients receiving secondary
or tertiary care, it forms the base for the stratification of
local diabetic patients into very high risk, high risk,
medium risk and low risk in the RAMP at primary care
level. Apart from stratifying diabetic patients into differ-
ent risk levels, equations integrating different patient’s
clinical parameters have been formulated to predict the
diabetic patient’s 5-year risk of coronary heart disease,
stroke, end-stage renal disease, and all-cause mortality
[12-15].
The goal of care for patients with DM is to prevent
DM-related complications such as cardiovascular dis-
eases and renal failure. Cardiovascular risk prediction
rules have been developed, mostly based on the Framing-
ham Study [16], but these may not be applicable to the
Asian or Chinese population [17,18]. Studies have shown
that the original Framingham functions might over-
estimate the risk of coronary heart disease (CHD) in Chin-
ese adults [18]. The Joint Asia Diabetes Evaluation (JADE)
equations have been formulated and tested on local data
from the Hong Kong Diabetes Registry showing good va-
lidity and discriminating power.
With the threat of aging population and the foreseeable
increase in demand of public primary healthcare ser-
vice on providing care to patients with chronic dis-
eases, programmes that can be proved to be effective
and provide a good quality of care are one of the
solutions to deal with the complexity and demand of
the health needs. Since DM is a common chronic
condition with diverse complications in our locality
as well as worldwide, we would like to evaluate the
QOC and the effectiveness of the RAMP to prove if
such kind of approach of chronic disease manage-
ment works.
The evaluation of QOC and effectiveness is an essen-
tial step in assessing a chronic disease management
programme on whether the intended care is provided
and the expected health benefit is achieved. The infor-
mation will influence future policy and service planning
related to healthcare.
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The aim of this study is to evaluate the quality of care
(QOC) and effectiveness of a multi-disciplinary risk as-
sessment and management programme (RAMP) for type
2 diabetic patients attending government-funded pri-
mary care clinics in Hong Kong. The evaluation will be
conducted using a structured and comprehensive
evidence-based evaluation framework.
The objectives of the study are:
1) To review and identify the structure, process and
outcome indicators of quality of care;
2) To identify the criterion and set the target standard
for each indicator;
3) To compare the observed standards against the
target standards;
4) To identify any on-site problems related to
implantation of the RAMP;
5) To provide feedback on quality of care of RAMP;
6) To identify possible areas for improvement;
7) To give recommendations for enhancement of
service delivery
The following hypotheses will be tested:
1) The structure and process criteria of care of different
aspects should be achieved up to standards in all
participating clinics;
2) A higher proportion of patients should have
achieved the outcome targets for HbA1c, blood
pressure, and LDL-C after the RAMP;
3) Patients participated in the RAMP should have
better clinical outcomes than non-participants
(control) managed by usual care;
4) Patients participated in the RAMP should not have
higher health service utilization rates than non-
participants (control) managed by usual care;
5) In longer terms, RAMP will lower the complication
rate and cardiovascular risk level of diabetic patients.
Methods/design
Evaluation of quality of care
A longitudinal study using the Action Learning [19] and
Audit Spiral methodologies [20] will be used to carry
out a systematic analysis of the quality of care, and to
identify areas for enhancement in a multi-disciplinary
approach to chronic disease management. Audit is the
best available tool to evaluate whether patients are re-
ceiving the best quality of care. It provides information
to the service provider on how to improve the quality of
health care delivery. It also reviews the procedures for
assessment of patients, service delivery, outcomes and
resources allocation. The audit can be regarded as a
spiral systematic process, with the ultimate goal ofimproving the quality of care. The audit consists of dif-
ferent cycles and as the audit cycle continues, each cycle
aims at a higher level of quality of care.
Development of the evaluation framework
Donabedian’s taxonomy of quality of care on structure,
processes and outcomes will be used as the evaluation
framework [21]. A QOC framework (Additional file 1)
was developed by an iterative process and reconciliation
between the investigators and the programme providers
(Figure 1). It started with the intensive literature review
on DM so that key elements of management of DM at
primary care level were grouped. Through iterative dis-
cussions with the working group (WG) of the health
care providers (HA) and the statistical team of the HA
on what aspects needed to be evaluated and what data
are retrievable from the computer system, the evaluation
framework gradually came into shape. This final eva-
luation framework listed out the indicators of the struc-
ture (staff, facilities, organization, and management),
process (what, when and how care is delivered), and out-
comes (clinical outcomes, service utilization and patient
reported outcomes) with the required criteria and target
standard of care to be achieved.
Evaluation of the effectiveness of RAMP
Effectiveness of the programme will be evaluated in
terms of clinical outcomes, service utilization outcomes,
and patient-reported outcomes. A cohort study will be
conducted on all eligible diabetic patients who have en-
rolled into RAMP for more than one year to compare
their clinical and public service utilization outcomes of
RAMP participants and non-participants. Clinical out-
come measures will include HbA1c, blood pressure
(both systolic and diastolic), lipids (low-density lipopro-
tein cholesterol); and the 5-yr and 10-yr cardiovascular
risk or coronary heart disease risk (by using appropriate
risk prediction equations). Public health service
utilization rate will include general and specialist out-
patient attendances, emergency department attendances,
and hospital admissions. This cohort of patients will be
followed up regularly and evaluated at assigned time-
points, i.e. 6, 12, 36 and 60 months after the start of the
study. For evaluation of the patient reported outcomes
(PRO), 550 diabetic patients enrolled into RAMP and
550 diabetic non-RAMP patients will be recruited for
telephone interview at the same time interval for their
PEI, GRS, and private health service utilization rate.
Subjects
All diabetic patients who have been enrolled into the
RAMP will be included in the evaluation on process of
care for each audit cycle. All enrolled subjects who have
been recruited for more than 12 months in the
Step 1: HKU evaluation team
drafted generic quality of care 
indicator framework 
Step 2: Programme WG defined 
indicators and criteria 
Step 3: HKU evaluation team
refined programme specific 
indicators, criteria & standards
Step 4: Programme WG
specified detailed setting of 
indicators, criteria & standards
Step 5: Programme WG and HKU 
evaluation team reconciliation on 
indictors, criteria, standards and 
operational definitions
Step 6: Programme WG reviewed 
and finalized the framework that 
is evidence-based and practical
Figure 1 An iterative process and reconciliation between the HKU evaluation team and the programme working group (WG).
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clinical outcomes of care for each audit cycle.
To identify the difference in programme perfor-
mance and impact between the two groups (RAMP
participants and non-participants), a cohort study ap-
proach would be adopted. The cohort includes all eli-
gible diabetic patients under care of the public
primary care outpatient clinics at 1 Sep 2009. The co-
hort would be evaluated annually on their clinical and
service utilization outcomes from September 2009 to
September 2015.
550 diabetic patients who have enrolled into the
RAMP and another 550 diabetic patients who have not
will be invited in person from the GOPCs by trained re-
search assistants at the beginning of each audit cycle to
take part in a telephone survey on PRO. All subjects
who have signed the written consent to the telephone
survey will be interviewed by telephone within four
weeks, at 6, 12, 36 and 60 months.
Sample size calculation
The sample size for the evaluation of quality of life
change after RAMP is estimated to detect a minimally
clinically important difference (MCID) in health-related
quality of life (HRQOL) studies that is equivalent to
Cohen’s small effect size of 0.3 [22]. A sample size of
350 patients in total (175 RAMP participants and 175
non-participants) is needed in order to have 80% power
and 95% confidence interval by independent T-test [23].
Therefore taking into consideration these factors and
allowing for a 25% dropout rate on each follow up, a
total of 1100 patients (550 RAMP participants and 550
non-participants) need to be recruited.
Data collection
Evaluation on structure and process
The coordinator of each of the seven clusters will be
asked to complete a Structure of Care Questionnaire(Additional file 2). Anonymised data will be retrieved
from the Hospital Authority’s patient information system
to determine the patient recruitment rate, enrolment
rate, risk level stratification, attendance at RAMP clinic,
compliance with assessment as per protocol, number of
investigations and referral rate. Information on patient
and provider characteristics will also be collected as in-
dependent variables. The doctor-in-charge of the RAMP
of each participating clinic will also complete the struc-
ture of care questionnaire (Additional file 2). We will
ask them to submit a list of the staff and facilities desig-
nated for the programme, and a description of the
programme objectives and protocol, and we will carry
out site visits to cross-validate the data.Evaluation on outcomes of care
Anonymised data on the relevant clinical outcomes, an-
nual attendance rates for GOPC, specialist outpatient
clinics (SOPC), A&E department and hospital admis-
sions at baseline, 12, 24, 36 and 48 months will be
retrieved from the Hospital Authority’s information sys-
tem. The data will be extracted using specific data col-
lection form. Data needed to calculate the future
cardiovascular risk prediction (e.g. urine albumin to cre-
atinine ratio) will be extracted from HA’s information
system.
The 550 RAMP participants and 550 non-participants
who have agreed to the telephone follow up will be con-
tacted by a trained research assistant who will obtain
written consent from each patient. Each patient will then
answer the Chinese (Hong Kong) Short Form-12 version
2 (SF-12v2) Health Survey within four weeks from enrol-
ment and a repeat survey at 6, 12, 36 and 60 months to-
gether with an assessment on patient enablement and
global rating of change in health condition and a struc-
tured questionnaire on private health service utilization
rates.
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An interim analysis of the standards of care, particularly
on the structure and process of care was carried out
6 months after the start date of the evaluation study to
identify major problems of programme implementation.
These results were fed back and discussed with the
programme team of HA to identify areas of deficiency
and quality enhancement strategies.
Three evaluation (audit) cycles on the standards of
care will be carried out at 15, 30 and 45 months from
the start of the study to evaluate whether the set stan-
dards of care on structure, process and outcomes have
been achieved (Figure 2). The first evaluation cycle is to
identify gaps between practice and intended targets that
may require changes in the structure and process of
care. The second evaluation cycle is to determine the
standards that are achievable after the programme has
been established. The third evaluation cycle is to assess
the sustainability of the standards of care. The results of
each evaluation cycle on the performance of the
programme will be fed back and discussed with the
programme team of the Hospital Authority to identify
any need for changes in quality criteria and standards
and corresponding quality enhancement strategies to be
implemented for RAMP.
Outcome measures
Primary
1. The proportion of clinics that have satisfied the
target of each of the structure criterion.
2. The number and proportion of diabetic patients who
have completed RAMP.
3. The proportion of patients who have complied with
the target of each of the process of care criterion.First evaluation on 
the standards of 
structure, process and 
outcome of care
Third evaluation on 
quality of care & 
effectiveness of 
programme
Second evaluation on 
the standards of 
structure, process and 
outcome of care
Figure 2 The audit spiral with three evaluation (audit) cycles.4. The proportion of patients who have achieved the
target of each of the outcome of care criterion,
mainly the control of DM, as reflected by HbA1c.
5. DM-related complication rates, e.g. coronary heart
disease, stroke, all-cause mortality, etc.
6. The predicted 5-year / 10-year cardiovascular risk, by
using the risk prediction equations.
Secondary
1. The change in risk level of diabetic patients after
RAMP
2. Other clinical outcomes, including SBP, DBP, LDL-C,
and body mass index.
3. PRO measured by the change in SF-12v2 scores, the
PEI and GRS scores at 6, 12, 36 and 60 months.
4. Service utilization outcomes measured by GOPC and
SOPC attendance rates, A&E and hospital admission
rates in the past 12 months.
Study instruments
Study instruments will be used in evaluating the struc-
ture of care and the PRO. Evaluation of the process of
care and outcomes do not involve use of study instru-
ments as the necessary data is to be retrieved from the
HA through the statistical team.
Structure of care questionnaire
Structure of care questionnaire will be sent to the cluster
co-ordinators and clinic doctors in-charge of the RAMP
and require their input. The questionnaire covers ques-
tions on resources spent on RAMP, e.g. whether there is
enough space for the programme, whether there is a
data sharing platform within the programme, etc.Feedback of results to 
Programme WG; 
review criteria &
standards; action plan 
for improvement
Programme WG and 
HKU evaluation 
team set target 
criteria & standards
Feedback of results to 
Programme WG; 
review criteria & 
standards; action plan 
for improvement
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the PRO, namely the short form-12 version 2 Health
Survey, the Patient Enablement Instrument, and the
Global Rating Scale.
A. The short form-12 version 2 (SF-12v2) Health
survey
The Chinese (Hong Kong) SF-12v2 Health Survey
will be used to measure HRQOL. It has been
validated and normed on the general Chinese
population in Hong Kong [24]. It measures eight
domains of HRQOL on physical functioning, role
physical, bodily pain, general health, vitality, social
functioning, role emotional and mental health on a
scale range from 0 to 100. A higher score indicates
better HRQOL. The eight domain scores can be
summarized into two summary scores, the physical
(PCS) and mental (MCS) component summary.
B. The Patient Enablement Instrument (PEI)
The PEI is a measure of patient’s enablement in
coping with the illness and life [25]. It has 6 items
each rated on a 3-point (0, 1, and 2) scale. The
summation of the item scores gives the PEI score
with a higher score indicating better enablement.
The PEI has been translated into Chinese and shown
to be valid and reliable in the general Chinese
population [26].
C. The Global Rating Scale (GRS)
The GRS is adapted from those used in studies by
Jaeschke and Osoba et al. [27]. It assesses the
subject’s global perception of any change in the
overall health condition on a 7-point scale (−3, -2,
-1, 0, 1, 2, and 3) over the last six months.
Data analysis
Descriptive statistics on standard of care will be calcu-
lated by the percentage of clinics meeting the structure
criteria, and percentage of subjects enrolled, attended,
completed the programme, receiving criterion process of
care, investigations and referral per protocol, and per-
centage of subjects achieving the criterion outcomes of
care, in each audit cycle, and at the end of five years.
Moreover, our primary analysis will use cardiovascular
disease (CVD) risk-prediction algorithm according to
the Framingham Heart Study [16]. This equation pre-
dicts the 10-year risk of CVD events which is defined as
a composite of CHD (coronary death, myocardial infarc-
tion, coronary insufficiency, and angina), cerebrovascular
events (including ischemic stroke, haemorrhagic stroke,
and transient ischemic attack), peripheral artery disease
(intermittent claudication), and heart failure. The equa-
tion is applicable to patients aged 30–74 years. As a
means of cross-validation and comparison, the predicted
5-year cardiovascular risk will also be estimated by thelocally validated JADE equations [12-15]. In addition,
within-subject improvement in outcomes from baseline
at 12, 24, 36 and 48 months will be analysed by paired t-
test for continuous outcomes and McNemar test for
binary outcomes. Furthermore, differences in outcomes
between RAMP participants and non-participants, be-
tween audit cycles will be tested by analysis of variance
(ANOVA) for continuous outcomes and Chi-square test
for categorical outcomes. We will also compare the
baseline frequency of attendance between RAMP partici-
pants and non-participants as a proxy measure of their
motivation to care. Self-selection biases will be examined
over inter-subject and inter-group differences by analysis
of covariance. Adjustment for multiplicity where appro-
priate will be made by Bonferroni adjustment. At last,
multiple regressions will be used to identify factors that
are associated with quality of care or effectiveness of the
RAMP.
Ethics Approvals
This study has received ethics approval from the Institu-
tional Review Board of the University of Hong Kong/
Hospital Authority Hong Kong West (UW 10–369),
Hong Kong East (HKEC-2010-093), Kowloon East and
Kowloon Central (KC/KE-10-0210/ER-3), Kowloon West
(KW/EX/10-317 (34–04)), New Territories East (CRE-
2010.543), and New Territories West clusters (NTWC/
CREC/1091/12).
Discussion
Quality assurance exercise on such a scale has never
been conducted in our settings, and only few have been
conducted in Asia. Careful attention is required to facili-
tate coordination between the various parties. This is the
first territory wide study to evaluate the quality of care
of a complex systematic intervention for diabetic
patients in Hong Kong. The results can assure the qual-
ity and determine the effectiveness of this multi-
disciplinary programme in improving the health and
health-related outcomes for patients with DM. Possible
areas for quality enhancement will be identified and
standards of good practice can be established. Action re-
search requires the engagement of key stakeholders’
right from the beginning of protocol development and
readiness to make changes in response to new issues
that merged during the study process. Close collabor-
ation with the programme administrator and providers
are vital so that the results are valid and that recommen-
dations made are feasible and acceptable.
Coordination of stakeholder collaboration and
communication
As the study involved health policy decision makers,
Hospital Authority administrators and other staff from
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service from seven regional clusters in addition to nu-
merous frontline clinical staff, adequate and open chan-
nels for communication is essential for the smooth
facilitation of the project. A senior project coordinator
and single point of call representing the academic inves-
tigators and Hospital Authority teams helps to facilitate
and streamline communication and arrangement of ac-
tivities such as meetings, site visits, subject recruitment
(for PRO) and monitoring of data collection.
Regular planning and feedback meetings are required
to ensure all parties receive timely updates to the status
of the evaluation and sharing of interim findings. The
use of an iterative process is useful to facilitate stakeholder
participation, however, careful planning is required to
allow for efficient and effective two-way communica-
tion. Modifications to the evaluation framework, data
collection and dissemination of results require endorse-
ment by the decision-makers and the establishment of
working groups is an effective way to manage the ad-
ministrative and logistical challenges encountered when
dealing with multiple parties.Feedback and planning meetings
Continuous communication and regular meetings with
the working group, frontline staff, and statistical team is
crucial in this continuous process of evaluation. Feed-
backs and interim reporting help to identify deficiencies
and direction of change at an earlier phase of the whole
process of evaluation. Arrangement of site visit to the
involved outpatient clinic and discussion with the front-
line staff in addition to observation can help cross vali-
date the accuracy of the data.Stakeholder endorsement and validation
In a programme of this scale, small variations in
programme protocol are inevitable between sites. Every
clinic needs to be able to have the flexibility to introduce
their own refinements tailored specifically to accommo-
date the needs of their patient population. Other factors
such as changes in availability of staff, space, and fluc-
tuations in patient load can also contribute to variations
in protocol delivery. To accommodate these variations,
it is essential to verify with all participating clinics that
the same operation skeleton is maintained and modifica-
tions from the protocol be minimised and maintained
within an acceptable limits in order to totally reflect the
performance and impact of the RAMP.
Furthermore, site visits to the clinics are an effective
way to identify any potential on-site problems encoun-
tered in the actual implementation of the programme
and suggest possible solutions.Development of the evaluation framework
The indicators and benchmark standards of care for the
evaluation framework were derived from literature re-
view and international and local management guidelines.
However, research-based evidence is not always available
for every criterion. In these circumstances, a comprom-
ise between best practice and local practice needs to be
agreed upon with both policy decision makers and cli-
nical healthcare providers. Furthermore, clear operation
definitions are required to describe what is being mea-
sured, for example, explicit definitions for referral rates,
enrolment rates and attendance rates need to be agreed
to ensure that the information collected is accurate and
interpretable.
Defining the target standards for each criterion of care
is also essential and requires a fine balance between
standards which are ideal and standards which are fea-
sible. While the standard of care should be set appro-
priately high to allow room for improvement, it must
still be realistic for use in real clinical settings.
Operation definitions
In order to ensure the reliability of the responses of the
Structure of Care Questionnaires, and to define clearly
what exact information is needed and what exact data
should be retrieved, operation definitions are set and
supplemented to the evaluation reference framework so
that the interpretation of the framework is standardized.
Clear articulation, field testing, and modification of
poorly understood items are required to avoid misinter-
pretation and assure accurate data collection, and it can
be accomplished with the interim evaluation.
Monitoring and ensuring data quality
Anonymised data on the process of care, clinical out-
comes, and service utilization outcomes is extracted
from the Hospital Authority’s information system. How-
ever, there may be substantial amount of missing data on
clinical outcomes of care particularly for non-participants.
It is because while one of the advantages of having RAMP
is to ensure regular checking of patients’ clinical para-
meters like HbA1c, urine albumin-to-creatinine ratio, etc.,
patients who have not taken in RAMP (non-participants)
are not secured to have these clinical outcomes checked
regularly and their clinical data may not be as comprehen-
sive as that for patients who have enrolled into RAMP
(RAMP participants). Moreover, some information such
as the duration of having DM of both RAMP participants
and non-participants are self-reported which significantly
influences the information accuracy. Therefore, every
piece of information collected should be interpreted care-
fully in an attempt to truly reflect the performance and
impact of the programme. To address these problems, it is
important to discuss with the health policy decision
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sible to collect the valid information as much as possible
and the acceptable sampling period should be made.
Thereupon, the operation definition for the information
needed should be concluded (Additional file 1). For
example, for the reading of HbA1c at baseline, the
last available reading prior to the date of RAMP enrol-
ment rather than those after should be adopted. The
last HbA1c reading available in 9–15 months after RAMP
enrolment should be used as the post-12 months reading.
Conclusion
With the expected increasing numbers of patients with
chronic diseases like DM, a well-organized and compre-
hensive multi-disciplinary approach to care will be the
preferred model of healthcare delivery. Formal eva-
luation studies are needed to provide evidence that these
models help to enhance the quality of care offered and
received by the patients. If proven effective, similar multi-
disciplinary models can be developed for management of
patients with other chronic diseases like hypertension,
chronic obstructive sleep apnoea, or osteoporosis at the
primary care level. Studies looking to establish evidence
for these models of care will be of considerable interest
to health care planners, particularly when aging popula-
tion is the global trend.
Additional files
Additional file 1: Quality of Care Evaluation Framework.
Additional file 2: Structure of care questionnaire.
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PRO: Patient reported outcomes; CVD: Cardiovascular disease;
ANOVA: Analysis of variance.
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